A reporter cell line for the automated quantification of SARS-CoV-2 infection in living cells

The SARS-CoV-2 pandemic and the urgent need for massive antiviral testing highlighted the lack of a good cell-based assay that allowed for a fast, automated screening of antivirals in high-throughput content with minimal handling requirements in a BSL-3 environment. The present paper describes the c...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in microbiology Vol. 13; p. 1031204
Main Authors Desmarets, Lowiese, Callens, Nathalie, Hoffmann, Eik, Danneels, Adeline, Lavie, Muriel, Couturier, Cyril, Dubuisson, Jean, Belouzard, Sandrine, Rouillé, Yves
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media 29.09.2022
Frontiers Media S.A
Subjects
Online AccessGet full text
ISSN1664-302X
1664-302X
DOI10.3389/fmicb.2022.1031204

Cover

More Information
Summary:The SARS-CoV-2 pandemic and the urgent need for massive antiviral testing highlighted the lack of a good cell-based assay that allowed for a fast, automated screening of antivirals in high-throughput content with minimal handling requirements in a BSL-3 environment. The present paper describes the construction of a green fluorescent substrate that, upon cleavage by the SARS-CoV-2 main protease, re-localizes from the cytoplasm in non-infected cells to the nucleus in infected cells. The construction was stably expressed, together with a red fluorescent nuclear marker, in a highly susceptible clone derived from Vero-81 cells. With this fluorescent reporter cell line, named F1G-red, SARS-CoV-2 infection can be scored automatically in living cells by comparing the patterns of green and red fluorescence signals acquired by automated confocal microscopy in a 384-well plate format. We show the F1G-red system is sensitive to several SARS-CoV-2 variants of concern and that it can be used to assess antiviral activities of compounds in dose–response experiments. This high-throughput system will provide a reliable tool for antiviral screening against SARS-CoV-2.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMCID: PMC9558224
Reviewed by: Jun Wang, Rutgers, The State University of New Jersey, United States; Eve-Isabelle Pecheur, INSERM U1052 Centre de Recherche en Cancerologie de Lyon, France
This article was submitted to Virology, a section of the journal Frontiers in Microbiology
Edited by: Shiu-Wan Chan, The University of Manchester, United Kingdom
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2022.1031204